Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
Decoding the Future of Multiple Myeloma: A Sneak Peek into the Top Abstracts of Multiple Myeloma at 2024 European Hematology Association (EHA) Congress
- Home
- EHA Conference
- multiple myeloma top abstracts eha 2024
Multiple Myeloma Top Abstracts | EHA 2024
The market for multiple myeloma is rapidly evolving, and current and emerging key players face the biggest risk due to this high degree of innovation. Antibody-drug-conjugates (ADCs), CAR-T cell treatments, and bispecific antibodies are just a few of the novel modes of action that have recently entered the market for the treatment of Multiple Myeloma.
In frontline multiple myeloma clinical studies, DARZALEX was successful and is now considered the standard of therapy. DARZALEX has outperformed rivals' expectations in terms of effectiveness and safety and is expected to rule the multiple myeloma market.
A second CD38 antibody called SARCLISA has been approved for treating multiple myeloma. SARCLISA continues its rapid acceptance in key markets. But DARZALEX has an advantage over SARCLISA of more than four years. Both monoclonal antibodies are competing against one another in a quadruplet regimen in both transplant-eligible and ineligible settings. The two CD38 antibodies are also close to a showdown in patients who are not eligible for transplant. This wave of evidences for the CD38-RVd combinations comes from studies in the transplant-eligible group.
Multiple myeloma is a promising therapeutic target due to the widespread expression of BCMA on myeloma cells. The field of BCMA-targeting drugs in multiple myeloma has undergone significant advancement. Introduction of CAR-T cell therapies ABECMA and CARVYKTI, and most recently TECVAYLI, are examples of the rise of the BCMA space in multiple myeloma.
Top pharmaceutical companies like Bristol Myers Squibb, Sanofi, AbbVie, GlaxoSmithKline, Gracell Biotechnologies (Astrazeneca), Johnson & Johnson Innovative Medicine, Regeneron, CARsgen, Roche and others are gearing up for the conference, ready to present initial, updated and final results. The upcoming session is highly anticipated for its unveiling of primary results from the Phase III IMROZ study, hoping to offer a potential treatment option for transplant-ineligible newly diagnosed multiple myeloma patients in combination with VRD. Additionally, the results of Ciltacabtagene Autoleucel from CARTITUDE-2 trial and, Belantamab results from DREAMM-7 will be of much interest during the EHA 2024.
In this context, DelveInsight has meticulously compiled a list of the top oral presentation abstracts related to multiple myeloma. These abstracts are on the verge of potentially transforming patient care in the future. They carry the potential for substantial progress, aiming to positively impact the treatment landscape of multiple myeloma.
Multiple Myeloma Key Abstracts
Executive Summary
The market for multiple myeloma is rapidly evolving, and current and emerging key players face the biggest risk due to this high degree of innovation.